Tech Company Financing Transactions
TearSolutions Funding Round
TearSolutions secured a $3 million Series B funding round on 11/21/2024. Backers included private investors.
Transaction Overview
Company Name
Announced On
11/21/2024
Transaction Type
Venture Equity
Amount
$3,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to accelerate its development programs for rare corneal diseases at both pre-clinical and clinical stages.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
315 Old Ivy Way 301
Charlottesville, VA 22903
USA
Charlottesville, VA 22903
USA
Phone
Website
Email Address
Not Recorded
Overview
Human tears supply and protect the surface of the eye. Several tear proteins are deficient in dry eye, the most common eye disease. One is essential and when reintroduced to dry eye tears, health is restored. Lacripep is a first-in-class topical synthetic peptide treatment for dry eye that addresses cause.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Mark Logan
Chief Executive Officer
Thomas Gadek
Chief Financial Officer
Colin Rolph
Chief Medical Officer
Marc Odrich
Chief Scientific Officer
Gordon Laurie
VP - Regulatory Affairs
Michelle Carpenter
Browse more venture capital transactions:
Prev: 11/21/2024: Echion Technologies venture capital transaction
Next: 11/21/2024: CellPoint Digital venture capital transaction
Share this article
News on VC Transactions
We report on funding rounds that are announced publicly. VC investment data records on this site are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs